Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Study of Immune Modulation During Palynziq® Treatment in Adults With Phenylketonuria (PKU)

NCT07477691 is registered in ClinicalTrials.gov with BioMarin Pharmaceutical as lead sponsor.

NCT NCT07477691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07477691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Study of Immune Modulation During Palynziq® Treatment in Adults With Phenylketonuria (PKU)
Lead sponsor
BioMarin Pharmaceutical
Phase
Phase 4
Overall status
Recruiting
Start date
May 29, 2026
Completion date
September 30, 2027
Enrollment
12 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

phenylketonuria